Refractory or Relapsed Diffuse Large B Cell Lymphoma
1 clinical trials · Condition
◉ Watch Refractory or Relapsed Diffuse Large B Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT06554600) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-08-31 |
Track Refractory or Relapsed Diffuse Large B Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.